University of Michigan Rogel Cancer Center
323
40
54
179
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
26.3%
85 terminated/withdrawn out of 323 trials
67.8%
-18.7% vs industry average
2%
6 trials in Phase 3/4
70%
125 of 179 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (323)
Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
Role: lead
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
Role: lead
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Role: lead
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
Role: lead
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
Role: lead
Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma
Role: lead
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
Role: lead
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
Role: lead
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)
Role: lead
A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families
Role: lead
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
Role: lead
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Role: lead
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
Role: lead
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Role: lead
Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors
Role: lead
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
Role: lead
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
Role: lead
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Role: lead
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
Role: lead
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
Role: lead